Big Pharma needs some big ideas. If it can’t find them — and turn them into the next blockbuster drugs — then it will be in Big Trouble. The clock is always ticking for the nation’s drug makers. That’s because drug patents last only 20 years. The… Read More

The phrase “failure of imagination” has returned to the lexicon. It may turn out to be an appropriate catchphrase for the just-ended 2000s. It also applies to a few situations on Wall Street, where investors seem unable to wrap their arms around the idea that things won’t… Read More

It’s become an annual tradition among the research staff of Market Advisor — StreetAuthority’s longest-running publication.   Every December, through phone calls, emails, and meetings — heck, everything short of smoke signals — the office is abuzz with chatter.   You see, December is when… Read More

The economy, at long last, has begun to recover. That’s not to say things are rosy. Unemployment is still 10%, and some suggest this means the nation’s recovery may be marked by less consumption and higher personal savings than in… Read More

Remember when big banks paid big dividends? Before the financial crisis Citigroup (NYSE: C) paid a quarterly dividend of $0.54; last quarter’s dividend was $0.01. Bank of America (NYSE: BAC) paid a per-share $0.64 quarterly dividend as recently as late 2008; December’s quarterly dividend… Read More

They say that beauty is in the eye of the beholder — and I suppose that’s just as true in the financial world as anywhere else. For most, the Fed‘s unprecedented string of stimulative rate cuts couldn’t have been better timed. Read More

You could take a stab at Medivation, Inc. (Nasdaq: MDVN), whose progress on Alzheimer’s treatment has sent its shares soaring three-fold since March. But then there’s OncoGenix Pharmaceuticals Inc. (Nasdaq: OGXI), whose shares famously fell more than -30% in short order (mostly in one… Read More

It was greeted as “an oddball security from Canada” when it debuted in December 2003. I’m speaking about one of the newest (and most lucrative) asset classes to hit Wall Street in recent years — enhanced income securities (EIS). The name… Read More

The S&P 500 lost ground during the past decade, but this drug maker’s shares returned a gravity-defying +1,179%. That’s the good news. The better news is that the company looks like it’s setting itself up for a repeat performance. Read More

Everyone likes a good list to start a new year. Whether it’s a “Top 10” of this or a “Best of” that, it’s always a fun exercise. But when it comes to picking stocks, nothing is as easy as it looks. If you’re an investor looking for… Read More